TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET END USER COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PORTERS FIVE FORCES 64
4.2 PESTEL ANALYSIS 65
5 INDUSTRY INSIGHTS: 66
6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 67
6.1 REGULATORY SCENARIO IN THE U.S 67
6.2 REGULATORY SCENARIO IN AUSTRALIA 67
6.3 REGULATORY SCENARIO IN JAPAN 68
6.4 REGULATORY SCENARIO IN CHINA 68
7 MARKET OVERVIEW 70
7.1 DRIVERS 72
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 72
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 72
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 72
7.2 RESTRAINTS 73
7.2.1 STRINGENT REGULATORY POLICIES 73
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 73
7.3 OPPORTUNITIES 74
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 74
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 75
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 75
7.4 CHALLENGES 76
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 76
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 77
8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 78
8.1 OVERVIEW 79
8.2 INSTRUMENTS 82
8.2.1 PATHOLOGY-BASED INSTRUMENTS 83
8.2.1.1 PCR INSTRUMENTS 83
8.2.1.2 SLIDE STAINING SYSTEMS 83
8.2.1.3 TISSUE PROCESSING SYSTEMS 84
8.2.1.4 CELL PROCESSORS 84
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 84
8.2.2 IMAGING INSTRUMENTS 84
8.2.2.1 ULTRASOUND SYSTEMS 84
8.2.2.2 CT SYSTEMS 84
8.2.2.3 MRI SYSTEMS 85
8.2.2.4 OTHERS 85
8.2.3 BIOPSY INSTRUMENTS 85
8.2.4 OTHERS 85
8.3 CONSUMABLES & ACCESSORIES 85
8.3.1 KITS 86
8.3.1.1 PCR KITS 86
8.3.1.2 DNA POLYMERASE KITS 86
8.3.1.3 NUCLEIC ACID ISOLATION KITS 86
8.3.1.4 OTHERS 87
8.3.2 REAGENTS 87
8.3.2.1 ASSAYS 87
8.3.2.2 BUFFERS 87
8.3.2.3 PRIMERS 87
8.3.2.4 OTHERS 87
8.3.3 OTHER CONSUMABLES 87
9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 88
9.1 OVERVIEW 89
9.2 STOOL EXAMINATION 92
9.3 BLOOD TEST 92
9.3.1 COMPLETE BLOOD COUNT (CBC) 93
9.3.2 TUMOR MARKER TEST 94
9.3.3 LIVER ENZYME BLOOD TEST 94
9.4 IMAGING TEST 94
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 95
9.4.2 MRI 95
9.4.3 ULTRASOUND 95
9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 96
9.4.5 OTHERS 96
9.5 TUMOR MARKERS 96
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 97
9.5.2 CA19-9 BIOMARKER TEST 97
9.5.3 CA 50 MARKER TEST 97
9.5.4 OTHERS 97
9.6 BIOPSY 97
9.7 OTHERS 98
10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 99
10.1 OVERVIEW 100
10.2 STAGE III 103
10.3 STAGE IV 103
10.4 STAGE II 104
10.5 STAGE I 105
10.6 STAGE 0 105
11 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 107
11.1 OVERVIEW 108
11.2 GERIATRIC 111
11.3 ADULTS 111
11.4 PEDIATRIC 112
12 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 114
12.1 OVERVIEW 115
12.2 ADENOCARCINOMA 118
12.3 COLORECTAL LYMPHOMA 118
12.4 GASTROINTESTINAL STROMAL TUMORS 119
12.5 CARCINOID TUMORS 120
12.6 OTHERS 120
13 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 122
13.1 OVERVIEW 123
13.2 HOSPITALS 126
13.3 DIAGNOSTIC CENTERS 126
13.4 CANCER RESEARCH CENTERS 127
13.5 AMBULATORY SURGICAL CENTERS 128
13.6 ACADEMIC INSTITUTES 128
13.7 OTHERS 129
14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 131
14.1 NORTH AMERICA 132
14.1.1 U.S. 141
14.1.2 CANADA 146
14.1.3 MEXICO 151
15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 156
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 156
16 SWOT ANALYSIS 157
17 COMPANY PROFILE 158
17.1 F. HOFFMANN- LA ROCHE LTD 158
17.1.1 COMPANY SNAPSHOT 158
17.1.2 REVENUE ANALYSIS 158
17.1.3 COMPANY SHARE ANALYSIS 159
17.1.4 PRODUCT PORTFOLIO 159
17.1.5 RECENT DEVELOPMENT 159
17.2 KONINKLIJKE PHILIPS N.V. 160
17.2.1 COMPANY SNAPSHOT 160
17.2.2 REVENUE ANALYSIS 160
17.2.3 COMPANY SHARE ANALYSIS 161
17.2.4 PRODUCT PORTFOLIO 161
17.2.5 RECENT DEVELOPMENT 161
17.3 THERMO FISHER SCIENTIFIC INC. 163
17.3.1 COMPANY SNAPSHOT 163
17.3.2 REVENUE ANALYSIS 163
17.3.3 COMPANY SHARE ANALYSIS 164
17.3.4 PRODUCT PORTFOLIO 164
17.3.5 RECENT DEVELOPMENT 164
17.4 ILLUMINA, INC. 165
17.4.1 COMPANY SNAPSHOT 165
17.4.2 REVENUE ANALYSIS 165
17.4.3 COMPANY SHARE ANALYSIS 166
17.4.4 PRODUCT PORTFOLIO 166
17.4.5 RECENT DEVELOPMENT 166
17.5 QUEST DIAGNOSTICS INCORPORATED 167
17.5.1 COMPANY SNAPSHOT 167
17.5.2 REVENUE ANALYSIS 167
17.5.3 COMPANY SHARE ANALYSIS 168
17.5.4 PRODUCT PORTFOLIO 168
17.5.5 RECENT DEVELOPMENT 168
17.6 ABBOTT 169
17.6.1 COMPANY SNAPSHOT 169
17.6.2 REVENUE ANALYSIS 169
17.6.3 PRODUCT PORTFOLIO 170
17.6.4 RECENT DEVELOPMENT 170
17.7 AGILENT TECHNOLOGIES, INC. 171
17.7.1 COMPANY SNAPSHOT 171
17.7.2 REVENUE ANALYSIS 171
17.7.3 PRODUCT PORTFOLIO 172
17.7.4 RECENT DEVELOPMENT 172
17.8 BD 173
17.8.1 COMPANY SNAPSHOT 173
17.8.2 REVENUE ANALYSIS 173
17.8.3 PRODUCT PORTFOLIO 174
17.8.4 RECENT DEVELOPMENT 174
17.9 BEIJING O&D BIOTECH CO., LTD. 175
17.9.1 COMPANY SNAPSHOT 175
17.9.2 PRODUCT PORTFOLIO 175
17.9.3 RECENT DEVELOPMENT 175
17.10 BIOFIRE DIAGNOSTICS 176
17.10.1 COMPANY SNAPSHOT 176
17.10.2 REVENUE ANALYSIS 176
17.10.3 PRODUCT PORTFOLIO 177
17.10.4 RECENT DEVELOPMENT 177
17.11 BIO-RAD LABORATORIES, INC. 178
17.11.1 COMPANY SNAPSHOT 178
17.11.2 REVENUE ANALYSIS 178
17.11.3 PRODUCT PORTFOLIO 179
17.11.4 RECENT DEVELOPMENT 179
17.12 CANON MEDICAL SYSTEMS CORPORATION. 180
17.12.1 COMPANY SNAPSHOT 180
17.12.2 REVENUE ANALYSIS 180
17.12.3 PRODUCT PORTFOLIO 181
17.12.4 RECENT DEVELOPMENT 181
17.13 FONAR CORP. 182
17.13.1 COMPANY SNAPSHOT 182
17.13.2 REVENUE ANALYSIS 182
17.13.3 PRODUCT PORTFOLIO 183
17.13.4 RECENT DEVELOPMENT 183
17.14 FUJIFILM CORPORATION 184
17.14.1 COMPANY SNAPSHOT 184
17.14.2 REVENUE ANALYSIS 184
17.14.3 PRODUCT PORTFOLIO 185
17.14.4 RECENT DEVELOPMENT 185
17.15 GE HEALTHCARE. 186
17.15.1 COMPANY SNAPSHOT 186
17.15.2 REVENUE ANALYSIS 186
17.15.3 PRODUCT PORTFOLIO 187
17.15.4 RECENT DEVELOPMENT 187
17.16 HOLOGIC, INC. 188
17.16.1 COMPANY SNAPSHOT 188
17.16.2 REVENUE ANALYSIS 188
17.16.3 PRODUCT PORTFOLIO 189
17.16.4 RECENT DEVELOPMENT 189
17.17 MEDONICA CO. LTD 190
17.17.1 COMPANY SNAPSHOT 190
17.17.2 PRODUCT PORTFOLIO 190
17.17.3 RECENT DEVELOPMENT 190
17.18 MERCK KGAA 191
17.18.1 COMPANY SNAPSHOT 191
17.18.2 REVENUE ANALYSIS 191
17.18.3 PRODUCT PORTFOLIO 192
17.18.4 RECENT DEVELOPMENT 192
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 193
17.19.1 COMPANY SNAPSHOT 193
17.19.2 PRODUCT PORTFOLIO 193
17.19.3 RECENT DEVELOPMENT 193
17.20 MYRIAD GENETICS, INC. 194
17.20.1 COMPANY SNAPSHOT 194
17.20.2 REVENUE ANALYSIS 194
17.20.3 PRODUCT PORTFOLIO 195
17.20.4 RECENT DEVELOPMENT 195
17.21 NEUSOFT CORPORATION 196
17.21.1 COMPANY SNAPSHOT 196
17.21.2 REVENUE ANALYSIS 196
17.21.3 PRODUCT PORTFOLIO 197
17.21.4 RECENT DEVELOPMENT 197
17.22 PLEXBIO 198
17.22.1 COMPANY SNAPSHOT 198
17.22.2 PRODUCT PORTFOLIO 198
17.22.3 RECENT DEVELOPMENT 198

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.